Amylyx is a pre-revenue biotech with one binary catalyst: Phase 3 LUCIDITY topline data for avexatide (GLP-1 receptor antagonist) in post-bariatric hypoglycemia (PBH), expected July-August 2026. The Q1 2026 earnings call on May 7 disclosed a cluster of commercial actions that don't typically appear before a positive Phase 3 readout. Two competing programs gave new readouts in the five days after the call. The picture has shifted enough to warrant the work.

What the filing says

Five operational actions are now public, all pre-readout. All five are downstream of one management decision — what the internal data look like — so treat them as a correlated signal cluster, not additive evidence:

1. Expanded Access Program launched for 250 PBH patients post-Roux-en-Y gastric bypass. Camille Bedrosian: "we recently launched a U.S. expanded access program to provide avexitide for up to 250 adults with PBH." Analyst Seamus Fernandez flagged it as atypical: "Typically we see companies sort of waiting for the completion of their Phase III, and then the announcement of an EAP in the wake of a positive Phase III."

2. NDA drafting active. Josh Klee: "We are already drafting NDA sections to support a potential submission... the last really substantial piece of work would be everything associated with the Phase III trial." Implies the rest is substantially built.

3. Chief Commercial Officer on call for the first time. Dan Monahan (background: Cosentyx/Novartis, REXULTI/Otsuka, Lantus/Sanofi). MSL team described as hired. Disease state education campaign launching summer 2026 — before the readout.

4. CMS ICD-10 code for PBH effective October 1, 2026 (announced April 2026). Validates the 160,000 US patient TAM claim and enables physician coding infrastructure pre-launch.

5. Trial powered to detect 35% effect vs 64% observed in Phase 2b at 90% power. Josh Cohen: "retaining power up to a 50% placebo effect... 90% powered to detect a clinically meaningful reduction, even under the most conservative circumstances."

Trial state: Last participant randomized late March 2026. Sixteen-week treatment period completes ~mid-July. Readout July-August. Earliest patients are already in the open-label extension.

Cash: $279.8M Q1-end. Normalized burn ≈$120-132M/year. Runway into 2028 reaffirmed.

What the market thinks

Market cap ≈$1.6B on ≈110M shares. September ATM IV 235% — implied move ≈75% in either direction. Front-month P/C open interest 0.07: options buyers overwhelmingly long calls, which reinforces the flat-to-call-positive skew read. 17.2% short interest is squeeze fuel if LUCIDITY hits. 11/12 sell-side Buy ratings, but $1.6B cap keeps generalist money out.

Our P_hit, derived

Prior: 50% — base rate for Phase 3 oncology/endocrine with positive Phase 2 + Breakthrough Therapy Designation + FDA-agreed endpoint.

LR stack (after correlation compression):

• Management cluster (EAP + NDA + CCO + MSL + ICD-10): one correlated signal, max(LR) ≈ 2.0
• MBX competitor exit (independent): 1.6
• Conservative trial powering: 1.5
• Insider selling unresolved: 0.7 (caps the stack)

Compressed net LR ≈ 2.0 × 1.6 × 1.5 × 0.7 ≈ 3.4. Posterior P ≈ 77%. Discount to 70% for unknown unknowns and the Relyvrio precedent (see Risks).

The gap — pick one assumption set

HIT target $32 derivation: 30K patients × $130K net price × 4-5x peak revenue multiple (Vertex 10x, Alnylam 7-8x, Sarepta 5x, Pharming 2.3x; using 4-5x for a category-leader rare orphan endocrine drug), PV-discounted four years at 25% biotech rate. Range $22-35, base $32. MISS floor $4: cash $2.54/share + minimal pipeline residual.

Two ways to read the gap, internally consistent:

Probability frame — assume both sides use HIT=$32. Current $14.56 implies P_market ≈ 38%. Our P=70%. Gap is 32 percentage points on probability.

Target frame — assume both sides use P=55-56% (options-implied from skew). The current price then implies a market HIT target of ≈$23-25, vs our $32. Gap is on the rerate target, not the probability.

Both interpretations are defensible from the tape. Either way, fair value at our assumptions: 0.70 × $32 + 0.25 × $4 + 0.05 × $8 = $23.80. Implied upside +63% from $14.56.

Why the gap exists:

• The EAP pre-readout signal is novel. Cross-corpus search found 4 mentions of "expanded access" + "Phase 3" in 10,607 earnings transcripts. The closest analog (RVMD daraxonrasib) launched EAP after positive Phase 3, not before. The signal hasn't been screened.
• MBX exited PBH on May 11, three days after AMLX's call. AMLX is now the de facto monopoly in GLP-1R antagonism PBH. Three days is not enough for the structural moat improvement to be priced.

The coordinated insider selling caps our prior at 70% rather than pushing higher.

Risks, ranked

1. LUCIDITY misses primary endpoint. P ≈25-30%. Impact: -65 to -80% to cash floor (≈$3.50-4.50). The binary itself dominates the risk profile.

2. Relyvrio precedent — what's different this time? Same management, same "conservative powering" language pre-PHOENIX fail (2024). PHOENIX failed because AMX0035 in ALS faced two regulatory novelties at once: a non-mechanistic compound (taurursodiol + sodium phenylbutyrate, multimodal/uncertain MoA in motor neuron disease) and an endpoint (ALSFRS-R + survival composite) the FDA had accepted with skepticism. PBH is structurally different: the pharmacological chain is direct and mechanistic — bariatric surgery alters anatomy → exaggerated GLP-1 release post-meal → hyperinsulinemia → hypoglycemia; avexatide blocks the GLP-1 receptor → breaks the chain. Phase 2b showed 64% reduction (p=0.0031). The endpoint (composite Level 2/3 hypoglycemic events through Week 16) is FDA-agreed registration-enabling. Mechanism-to-endpoint is one step, not several. Same team, different drug-mechanism-disease triad. The Relyvrio precedent calibrates downward but does not invalidate.

3. Insider selling is discretionary, not 10b5-1. Probability unknown until Form 4 footnote check. If discretionary, the management signaling cluster compresses to noise — slashes posterior P_hit from 70% to 55-60%.

4. Recordati gets FDA agreement on MMTT endpoint. Their PASIPHY Phase 2 hit on May 12 (p<0.02 MMTT glucose). Different mechanism (somatostatin), different endpoint. If FDA accepts MMTT as registration-enabling, Recordati moves to Phase 3 faster than expected and compresses AMLX peak revenue 15-20%.

5. Capital raise before readout. Would signal no insider data confidence and be highly dilutive at current price.

Catalysts and monitor list

What would strengthen conviction

• 8-K disclosing FDA pre-NDA meeting before readout — confirms management cluster
• Q2 EAP enrollment update >100 patients — validates 160K TAM and physician demand
• Form 4 footnotes confirm 10b5-1 plans pre-dating late-March enrollment completion

What would change our mind (bearish)

• Form 4 reveals discretionary insider selling, no 10b5-1 plan → P_hit to 55-60%, management cluster collapses
• Capital raise announcement before readout → signals no insider confidence
• LUCIDITY interim DSMB stop for futility → thesis dies
• Recordati announces FDA accepted MMTT endpoint → compress HIT target 15-20%

Sizing

Tenth-Kelly on the binary (p=0.70, win=+120%, loss=-73%) implies ≈6.3% of catalyst sleeve. The flat-to-call options skew makes downside protection cheap — a long + August $8 put structure converts the asymmetry from +120%/-73% to +120%/-45%.

Evidence

*Conditional on 10b5-1 plan status; drops to ≈0.5 if discretionary.

Memo LR signal: 1.4. Market underweights the cluster + MBX exit + favorable trial design. Edge is real but bounded by the unresolved insider gap.